News
MDGL
194.94
-4.74%
-9.71
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Madrigal Pharmaceuticals, Inc. Recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035. The company will have to overcome two challenges to maintain its "first mover" advantage in the market. Madrigal has to manage the launch of Rezdiffra and keep an eye on future competitors.
Seeking Alpha · 1d ago
3 Potential Biopharma Buyout Targets
Recent lack of M&A activity and rising interest rates have led to a 20% decline in small-cap biotech equities. Big Pharma's surplus of cash and key patent expirations should lead to increased M& a volume in the coming year. Three promising small biopharma names are attractive as standalone entities but would make logical buyout targets. Mirum Pharmaceuticals, Inc., ImmunoGen, Inc. And GLP-1 are three names that could be attractive.
Seeking Alpha · 2d ago
B of A Securities Initiates Coverage of Madrigal Pharmaceuticals (MDGL) with Underperform Recommendation
NASDAQ · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Vanda Pharma, Matterport
U.S. Stocks rose on Monday in choppy trading. The Dow Jones Industrial Average was up 1.01% at 38,371.51. The top three S&P 500 percentage gainers were Ford Motor Co, Nvidia and Vanda Pharma. The market is looking ahead to major tech earnings and a key inflation print this week. AZZ, Vanda Pharmaceutical and Matterport are up on the day.
Reuters · 3d ago
Madrigal Pharmaceuticals Becomes Oversold (MDGL)
NASDAQ · 3d ago
United Healthcare’s Favorable Insurance Coverage of Rezdiffra Boosts Madrigal Pharmaceuticals Buy Rating
TipRanks · 3d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardinal Health (CAH) and Madrigal Pharmaceuticals (MDGL)
TipRanks · 3d ago
REFILE-BUZZ-Madrigal Pharma falls as BofA initiates coverage with 'underperform' rating
Madrigal Pharma falls as BofA initiates coverage with 'underperform' rating. Shares of Madrigal Pharmaceuticals MDGL.O fall 6.3% to $198.69. Bofa forecasts peak sales of $4.1 billion below consensus estimates.
Reuters · 3d ago
MADRIGAL PHARMACEUTICALS SHARES DOWN 5.7% AFTER BOFA INITIATES COVERAGE WITH UNDERPERFORM RATING
Reuters · 3d ago
BofA Skipping Celebration of Madrigal's Rezdiffra -- Market Talk
Bank of America initiates coverage of Madrigal Pharmaceuticals with an underperform rating. BofA says payer pushback on the $47,000 annual price tag of the drug Rezdiffra could prompt a slow launch. The company scored the first FDA approval of a drug to treat the fatty liver disease known as MASH.
Dow Jones · 3d ago
Simplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And Beyond
Simplify Propel Opportunities ETF (SURI) is a healthcare-based fund that provides exposure to global fixed-income and equity markets in the healthcare sector. The fund offers a near-13% yield from its distributions. SURI has a since-inception return of -13%, but its recent performance has shown potential for growth.
Seeking Alpha · 3d ago
MADRIGAL PHARMACEUTICALS INC <MDGL.O>: BOFA GLOBAL RESEARCH INITIATES COVERAGE WITH UNDERPERFORM RATING; PRICE OBJECTIVE $150
Reuters · 3d ago
Madrigal Pharmaceuticals Initiated at Underperform by B of A Securities
Dow Jones · 3d ago
B of A Securities Initiates Coverage On Madrigal Pharmaceuticals with Underperform Rating, Announces Price Target of $150
Benzinga · 3d ago
Weekly Report: what happened at MDGL last week (0415-0419)?
Weekly Report · 3d ago
Hepion ends Phase 2 study for NASH drug due to cash restraints
Seeking Alpha · 5d ago
UPDATE 2-Organovo's drug significantly reduces liver fat in NASH study
Organovo's drug significantly reduces liver fat in NASH study. Shares of the small biotech firm surged 44% to $1.45 in early trading on Monday. Company's drug reduced liver fat by as much as 22.8% in a mid-stage study of some patients with NASH. The oral drug, FXR314, helped improve liver function.
Reuters · 04/15 12:23
Weekly Report: what happened at MDGL last week (0408-0412)?
Weekly Report · 04/15 09:24
2 Under-the-Radar Growth Stocks to Consider
Madrigal Pharmaceuticals recently earned approval for its first medicine on the market for a severe liver disease. Axsome Therapeutics has exciting possibilities in its pipeline. Madrigal has underperformed the market over the past year, but there could be plenty of upside for investors.
The Motley Fool · 04/10 14:15
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)
TipRanks · 04/10 00:15
More
Webull provides a variety of real-time MDGL stock news. You can receive the latest news about Madrigal Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About MDGL
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.